Cart
sales@molnova.com
VUF 10166
CAS No. 155584-74-0
VUF 10166( —— )
Catalog No. M17335 CAS No. 155584-74-0
VUF10166 is a novel, potent and competitive antagonist for 5-HT3A receptor with Ki of 0.04 nM, its affinity at 5-HT3AB receptor is significantly lower.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 10MG | 38 | In Stock |
|
| 25MG | 70 | In Stock |
|
| 50MG | 111 | In Stock |
|
| 100MG | 184 | In Stock |
|
| 200MG | 275 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVUF 10166
-
NoteResearch use only, not for human use.
-
Brief DescriptionVUF10166 is a novel, potent and competitive antagonist for 5-HT3A receptor with Ki of 0.04 nM, its affinity at 5-HT3AB receptor is significantly lower.
-
DescriptionVUF10166 is a novel, potent and competitive antagonist for 5-HT3A receptor with Ki of 0.04 nM, its affinity at 5-HT3AB receptor is significantly lower.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
Recptor5-HT3A| 5-HT3AB
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number155584-74-0
-
Formula Weight262.74
-
Molecular FormulaC13H15ClN4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (380.60 mM)
-
SMILESCN1CCN(CC1)C1=NC2=CC=CC=C2N=C1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Thompson AJ, et al. J Pharmacol Exp Ther, 2012, 341(2), 350-9.
molnova catalog
related products
-
Almonertinib mesylat...
Almonertinib mesylate is an irreversible inhibitor of EGFR tyrosine kinase with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate can be used in the non-small cell lung cancer studies.
-
CK-101
CK-101 (RX-518) is a novel potent, mutant-selective, irreversible, orally available EGFR inhibitor, overcomes T790M-mediated resistance in NSCLC.
-
Rezivertinib
Rezivertinib (BPI-7711) is an orally available, selective and potent inhibitor of tyrosine kinase (EGFR) with antitumor activity for central nervous system disorders.
